Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair

被引:0
作者
K Kudo
E Gavin
S Das
L Amable
L A Shevde
E Reed
机构
[1] Mitchell Cancer Institute,
[2] University of South Alabama,undefined
来源
Oncogene | 2012年 / 31卷
关键词
Gli1; ERCC1; XPD; XRCC1; cisplatin; ovarian cancer;
D O I
暂无
中图分类号
学科分类号
摘要
The transcription of ERCC1 and other nucleotide excision repair (NER) genes is strongly influenced by c-jun. C-jun is transcriptionally regulated by Gli proteins of the Hedgehog pathway. We therefore studied the possible relationships between Gli1, c-jun, and the upregulation of ERCC1, XPD and XRCC1 in cisplatin-resistant human ovarian cancer cells. We studied the paired human ovarian cancer cell lines A2780 and A2780-CP70. We used a shRNA construct that specifically degrades Gli1 message. Genes we assessed for mRNA and/or protein levels included: c-jun, ERCC1, XPD, XRCC1, Gli1, Gli2, SHH, IHH, GAPDH and α-tubulin. Platinum–DNA adduct repair was assessed by atomic absorbance spectrometry with Zeeman background correction. Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell's ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. This block in upregulation of c-jun was concurrent with a change in the phosphorylation pattern of the c-jun protein, shifting that pattern from a Ser63/73 dominant pattern, to a Thr91/93 dominant pattern. A2780-CP70 cells were treated at their cisplatin IC50, and DNA repair was assessed after pretreatment with anti-Gli1 shRNA or scrambled shRNA control. Control cells repaired 78% of platinum–DNA adducts at 12 h, compared with 33% repair in cells pretreated with anti-Gli1 shRNA resulting in a 2.4-fold difference. Pretreatment of A2780-CP70 cells with anti-Gli1 shRNA resulted in supra-additive cell killing with cisplatin; shifting the cisplatin IC50 (half maximal inhibitory concentration) from 30 μM to 5 μM. Pretreatment of these cells with cyclopamine did not shift the cisplatin IC50. We conclude that the transcriptional protein Gli1 is important in the upregulation of these three DNA repair genes in human ovarian cancer cells, and that Gli1 strongly influences platinum–DNA adduct repair, and cellular sensitivity to cisplatin. This Gli1 role has c-jun as an intermediate in the pathway. In all, inhibition of Gli1 by a specific shRNA inhibits the upregulation of c-jun Ser63/73, and also inhibits the upregulation of three genes essential to NER (ERCC1, XPD) and base excision repair (XRCC1).
引用
收藏
页码:4718 / 4724
页数:6
相关论文
共 221 条
[1]  
Reed E(2005)ERCC1 and clinical resistance to platinum-based therapy Clin Cancer Res 11 6100-6102
[2]  
Reed E(2006)ERCCI measurements in clinical oncology N Engl Med 355 1054-1055
[3]  
Reed E(2010)DNA damage and repair in clinical oncology: an overview Clin Cancer Res 16 4511-4516
[4]  
Reed E(1998)Nucleotide excision repair and anti-cancer chemotherapy Cytotechnology 27 187-201
[5]  
Reed E(1998)Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy Cancer Treat Rev 24 331-344
[6]  
Li Q(1998)Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells J Biol Chem 273 23419-23425
[7]  
Gardner K(1999)Modulation of ERCC-1 mRNA expression by pharmacological agents in human ovarian cancer cells Biochem Pharmacol 57 347-353
[8]  
Zhang L(2000)Proteasome inhibitors prevent cisplatin-DNA adduct repair and potentiate cisplatin-induced apoptosis in ovarian carcinoma cells Biochem Pharmacol 60 1343-1354
[9]  
Tsang B(1999)Phorbol ester exposure activates an AP-1 associated increase in ERCC1 mRNA expression in human ovarian cancer cells Cell Mol Life Sci 55 456-466
[10]  
Bostick-Bruton F(2009)Cooperation between Gli and Jun enhances transcription of Jun and selected Gli target genes Oncogene 28 1639-1651